GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Inventory Turnover

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Inventory Turnover : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. ImmuneOnco Biopharmaceuticals (Shanghai)'s Cost of Goods Sold for the six months ended in Jun. 2024 was HK$0.00 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Average Total Inventories for the quarter that ended in Jun. 2024 was HK$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory Turnover Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory Turnover Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventory Turnover
- - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Inventory Turnover Get a 7-Day Free Trial - - - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory Turnover Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover (Q: Jun. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Jun. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=0/0*365 / 2
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0 / 0.083
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

ImmuneOnco Biopharmaceuticals (Shanghai) Inventory Turnover Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Inventory Turnover
Comparable Companies
HKSE:06996 HKSE:06978 HKSE:02181 HKSE:01521 HKSE:02509 HKSE:02487 HKSE:02137 HKSE:02566 HKSE:02563 HKSE:01167 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
R9Z:Germany
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Tian Wenzhi 2501 Other
Yu Xiaoyong 2201 Interest of corporation controlled by you
Shang Hai Zhang Ke Ling Yi Sheng Fan Chuang Ye Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Shang Hai Zhang Jiang Ke Ji Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Lav Immon Hong Kong Limited 2101 Beneficial owner
Ho Yao
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Gba Fund Investment Limited 2101 Beneficial owner
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines